New immunotherapy attempts to fight childhood brain cancer
NCT ID NCT01795313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new immunotherapy approach for children whose ependymoma (a type of brain tumor) had come back after standard treatment. The therapy combined a peptide vaccine designed to train the immune system to attack tumor cells with a skin cream (imiquimod) that boosts immune response. The main goals were to check safety and see if the vaccine could activate the child's immune system against the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224, United States